CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.67% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money
2.0476
1.92%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.0948
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.024262 %
Charges from full value of position ($-4.61)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.024262%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.00204 %
Charges from full value of position ($0.39)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.00204%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 2.0876
Open 2.1376
1-Year Change 224.27%
Day's Range 1.8676 - 2.1376
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 13, 2024 2.0476 -0.0400 -1.92% 2.0876 2.1376 1.8476
Dec 12, 2024 2.0876 -0.1000 -4.57% 2.1876 2.1976 2.0876
Dec 11, 2024 2.1576 -0.1300 -5.68% 2.2876 2.3776 2.1476
Dec 10, 2024 2.3876 -0.0900 -3.63% 2.4776 2.4776 2.2876
Dec 9, 2024 2.4576 0.0200 0.82% 2.4376 2.4876 2.3876
Dec 6, 2024 2.4576 0.0700 2.93% 2.3876 2.5076 2.3876
Dec 5, 2024 2.3976 -0.0400 -1.64% 2.4376 2.4476 2.3876
Dec 4, 2024 2.4476 0.0100 0.41% 2.4376 2.5476 2.3976
Dec 3, 2024 2.4876 -0.0200 -0.80% 2.5076 2.5076 2.3976
Dec 2, 2024 2.5176 0.0200 0.80% 2.4976 2.5676 2.3876
Nov 29, 2024 2.5076 0.1100 4.59% 2.3976 2.5176 2.3876
Nov 27, 2024 2.4076 0.1700 7.60% 2.2376 2.4876 2.2376
Nov 26, 2024 2.2676 -0.1200 -5.03% 2.3876 2.3976 2.1176
Nov 25, 2024 2.2676 0.1300 6.08% 2.1376 2.2676 2.0976
Nov 22, 2024 2.1176 -0.1800 -7.83% 2.2976 2.3376 2.0576
Nov 21, 2024 2.2776 -0.3600 -13.65% 2.6376 2.7076 2.1676
Nov 20, 2024 2.7076 -0.0300 -1.10% 2.7376 2.7876 2.5876
Nov 19, 2024 2.7476 -0.0400 -1.43% 2.7876 2.9476 2.6376
Nov 18, 2024 2.7676 -0.1700 -5.79% 2.9376 2.9376 2.7376
Nov 15, 2024 2.9376 -0.1600 -5.17% 3.0976 3.1376 2.7876

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 3:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

HOOKIPA Pharma Inc. Company profile

About Hookipa Pharma Inc

HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company. The Company develops immunotherapeutics based on its arenavirus platform that are designed to target and amplify a T cell and immune response to disease. The Company's infectious and oncology product candidates HB-101, HB-201, HB-202 and HB-300. The infectious disease product candidate, HB-101, is in a randomized, double-blinded Phase II clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates, HB-201 and HB-202, are in development for the treatment of human papillomavirus-positive cancers. The Company is developing its self-antigen project in this area, HB-300, as a replicating technology-based product candidate in metastatic, hormone-resistant prostate cancer.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Hookipa Pharma Inc revenues increased 1% to $14.6M. Net loss increased 72% to $54.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 60% to $58M (expense), Other income and expenses, net decrease from $1.6M (income) to $1.3M (expense).

Industry: Pharmaceuticals (NEC)

The Empire State Building
350 Fifth Avenue, Room/Suite 7240
NEW YORK
NEW YORK 10118
US

People also watch

US100

21,741.60 Price
+0.640% 1D Chg, %
Long position overnight fee -0.0243%
Short position overnight fee 0.0020%
Overnight fee time 22:00 (UTC)
Spread 7.0

Gold

2,648.80 Price
-1.210% 1D Chg, %
Long position overnight fee -0.0125%
Short position overnight fee 0.0043%
Overnight fee time 22:00 (UTC)
Spread 0.60

ETH/USD

3,849.52 Price
-1.400% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 1.75

XRP/USD

2.39 Price
-1.930% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 0.01190

Still looking for a broker you can trust?

Join the 660,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading